The Leeds Teaching Hospitals NHS Trust

Clinical Trials

Hepatology & Liver Transplantation Trials

Open to recruitment:

  • Organ Care System (OCS™) Liver ‘REVIVE’ Trial
  • LIFT Liver Immunosuppression-free trial
  • UK PBC genetics study
  • UK PSC genetics study
  • STOP HCV Cirrhosis study
  • PROSPER (Prospective Real World Outcomes Study of Hepatic Encephalopathy Patients’ Experience of Rifaximin)
  • UK-AIH (United Kingdom Autoimmune Hepatitis Cohort)
  • A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure
  • AbbVie - A single arm, open label, multicentre study to evaluate the safety and efficacy of ABT-493/ABT-530 in adult post liver or post renal transplant recipients with chronic hepatitis c virus genotype 1-6 (MAGELLAN-2)
  • GILEAD - A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects with Chronic HCV Infection who have received a Liver Transplant

Open trials in follow-up:

  • An Open-Label, Multicenter Study to EvaluateLong-Term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)
  • TACE-2 Research trial evaluating sorafenib in combination with chemoembolization in patients with unresectable advanced Hepatocellular Carcinoma

Trials in set-up:

  • UK Nested PBC Study

Previous trials now closed:

  • WAFT-C Warfarin Anticoagulation for liver fibrosis in patients transplanted for HCV
  • LEAN Liraglutides Action and efficacy in NASH
  • ELUCIDATE ELF to Uncover Cirrhosis as an indication for Diagnosis and action for treatable events
  • ELUCIDATE patients experience
  • GILEAD A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection
  • ATTAIN(Retreatment of null and partial responders with TMC435) A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial responders to prior PegIFNα and ribavirin therapy
  • DILIGEN Pharmacogenetics of drug induced liver injury
  • STOPAH. Steriods or Pentooxifylline for Alcoholic Hepatitis
  • Drug Utilization of DAAs and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Patients
  • Hepatitis C Rimantadine and Antiviral Combination Therapy – “HepRiACT” trial

HPB Trials

Open trials in follow-up:

  • PRINGLE – Randomised Controlled Trial of Pringle Manoeuvre versus Portal Vein Clamping in Patients undergoing Liver Resection for Colorectal Liver Metastasis – A Pilot Study

Previous trials now closed:

  • EVARREST – A Phase III Randomized, Controlled, Superiority Study Evaluating EVARREST™ Fibrin Sealant Patch Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Hepatic Surgery
  • EPOC B -An exploratory study to investigate the optimal scheduling of chemotherapy in patients with operable colorectal liver metastases